hetacillin (versapen) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Hetacillin is a beta-lactam antibiotic that is part of the aminopenicillin family. It is a prodrug and has no antibacterial activity itself, but quickly splits off acetone in the human body to form ampicillin, which is active against a variety of bacteria.   Wikipedia

Chemistry

  • SMILES: CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O
  • InChIKey: DXVUYOAEDJXBPY-NFFDBFGFSA-N
  • Mol. Mass: 389.48
  • ALogP: 1.41
  • ChEMBL Molecules:
    hetacillin  
    hetacillin potassium  
More Chemistry

Pharmacology

Alternative names

(2s,5r,6r)-6-[(4r)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | 6beta-[(4r)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid | bl-p-804 | brl-804 | etacillin | hetacilina | hetacillin | hetacillin, (2s-(2alpha,5alpha,6alpha))-isomer | hetacillin, aluminum salt (3:1), (2s-(2alpha,5alpha,6beta(s*)))-isomer | hétacilline | hetacillin, monopotassium salt, (2s-(2alpha,5alpha,6beta(s*)))-isomer | hetacillin, monosodium salt, (2s-(2alpha,5alpha,6beta))-isomer | hetacillin, monosodium salt, (2s-(2alpha,5alpha,6beta(s*)))-isomer | hetacillin potassium | hetacillinum | hetacin | natacillin | penplenum | phenazacillin | versapen | versapen-k

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Bacterial Infections (approved 1971)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue